Phaik-Eng Sum
American Cyanamid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Phaik-Eng Sum.
Bioorganic & Medicinal Chemistry Letters | 2009
Darrin William Hopper; Matthew D. Vera; David Brian How; Joshua James Sabatini; Jason Shaoyun Xiang; Manus Ipek; Jennifer R. Thomason; Yonghan Hu; Eric Feyfant; Qin Wang; Katy E. Georgiadis; Erica Reifenberg; Richard Sheldon; Cristin Keohan; Manas K. Majumdar; Elisabeth A. Morris; Jerauld S. Skotnicki; Phaik-Eng Sum
The prevention of aggrecan (a key component of cartilage) cleavage via the inhibition of aggrecanase-1 may provide a unique opportunity to stop the progression of cartilage degradation in osteoarthritis. The evaluation of a series of biphenylsulfonamides resulted in the identification of the ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides analogs (19-21 and 24) with improved Agg-1 inhibition and MMP-2, MMP-13 activity.
Tetrahedron Letters | 1994
Phaik-Eng Sum; Ving J. Lee; Francis P. Tally
Abstract The C-8 functionalization of tetracycline derivatives via acid-catalyzed rearrangement of 7(or 9)azidotetracyclines is described. These compounds are the first to be prepared from an intact tetracycline nucleus.
Expert Opinion on Drug Discovery | 2007
Evan Loh; Evelyn J. Ellis-Grosse; Peter J. Petersen; Phaik-Eng Sum; Steven J. Projan
The emergence of pathogenic bacteria resistant to virtually all available antibacterial agents at present has caused consternation among medical professionals, but has only intermittently raised concern among the public. This has led to a transient resurgence of interest in studying the mechanisms of resistance and in discovering and developing new antibacterial agents, but successes in the development of novel antibacterial agents have been few and far between. Although it has been known since the discovery of the tetracyclines that they are inhibitors of protein synthesis, there has been considerable recent progress on elucidating the mechanisms of action of the tetracyclines and in the enhanced understanding of the mechanisms of tetracycline resistance. In this case study, the authors discuss the discovery and development of a new class of antibacterials, which were derived from the tetracyclines, namely the glycylcyclines. This has resulted in the introduction of a new agent, tigecycline, to clinical practice. The glycylcyclines restore the antibacterial activity to levels of the earlier tetracyclines when they were first introduced, by overcoming the two major tetracycline-resistance mechanisms of efflux and ribosome protection, which promises to have a high degree of clinical utility.
Archive | 1994
Joseph Mark Backer; Peter Bohlen; Phaik-Eng Sum
Archive | 1994
Joseph J. Hlavka; Phaik-Eng Sum; Yakov Gluzman; Ving J. Lee; Adma A Ross
Archive | 1994
Phaik-Eng Sum; Ving J. Lee; Raymond T. Testa
Archive | 1992
Joseph J. Hlavka; Phaik-Eng Sum; Yakov Gluzman; Ving J. Lee
Archive | 1994
Phaik-Eng Sum; Ving J. Lee; Joseph J. Hlavka; Raymond T. Testa
Archive | 1992
Phaik-Eng Sum; Ving J. Lee
Archive | 1994
Phaik-Eng Sum; Ving J. Lee; Joseph J. Hlavka; Raymond T. Testa